S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
NASDAQ:OXFD

Oxford Immunotec Global Stock Forecast, Price & News

$21.99
+0.01 (+0.05 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.97
Now: $21.99
$21.99
50-Day Range
$21.84
MA: $21.93
$21.98
52-Week Range
$8.37
Now: $21.99
$23.11
Volume808,562 shs
Average Volume1.10 million shs
Market Capitalization$570.90 million
P/E RatioN/A
Dividend YieldN/A
Beta1.42
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Oxford Immunotec Global logo

Headlines

PerkinElmer to Acquire Oxford Immunotec Global PLC
January 7, 2021 |  finance.yahoo.com
Is OXFD A Good Stock To Buy Now?
December 18, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OXFD
CUSIPN/A
Phone44-0-12-3544-2780
Employees273
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$73.71 million
Cash Flow$0.02 per share
Book Value$8.08 per share

Profitability

Net Income$-1,810,000.00

Miscellaneous

Market Cap$570.90 million
Next Earnings Date3/8/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.14 out of 5 stars

Medical Sector

933rd out of 1,972 stocks

Diagnostic Substances Industry

18th out of 32 stocks

Analyst Opinion: 1.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$21.99
+0.01 (+0.05 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OXFD News and Ratings via Email

Sign-up to receive the latest news and ratings for OXFD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions

Is Oxford Immunotec Global a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Oxford Immunotec Global stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXFD, but not buy additional shares or sell existing shares.
View analyst ratings for Oxford Immunotec Global
or view top-rated stocks.

What stocks does MarketBeat like better than Oxford Immunotec Global?

Wall Street analysts have given Oxford Immunotec Global a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oxford Immunotec Global wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Oxford Immunotec Global's next earnings date?

Oxford Immunotec Global is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Oxford Immunotec Global
.

How were Oxford Immunotec Global's earnings last quarter?

Oxford Immunotec Global PLC (NASDAQ:OXFD) released its quarterly earnings results on Tuesday, November, 3rd. The company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). The company earned $19.44 million during the quarter, compared to the consensus estimate of $18.58 million. Oxford Immunotec Global had a negative net margin of 30.51% and a negative trailing twelve-month return on equity of 8.39%.
View Oxford Immunotec Global's earnings history
.

How has Oxford Immunotec Global's stock price been impacted by Coronavirus (COVID-19)?

Oxford Immunotec Global's stock was trading at $12.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OXFD stock has increased by 80.4% and is now trading at $21.99.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for OXFD?

2 analysts have issued 1-year target prices for Oxford Immunotec Global's stock. Their forecasts range from $22.00 to $22.00. On average, they expect Oxford Immunotec Global's share price to reach $22.00 in the next year. This suggests a possible upside of 0.0% from the stock's current price.
View analysts' price targets for Oxford Immunotec Global
or view top-rated stocks among Wall Street analysts.

Who are Oxford Immunotec Global's key executives?

Oxford Immunotec Global's management team includes the following people:
  • Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 47, Pay $1.11M)
  • Mr. Matthew T.E. McLaughlin, Chief Financial Officer (Age 44, Pay $527.45k)
  • Ms. Janet Louise Kidd, Gen. Counsel & Company Sec. (Age 51)
  • Dr. Peter Edwardson, Sr. VP & Head of Blood Screening (Age 59)
  • Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 60)

What is Peter Wrighton-Smith's approval rating as Oxford Immunotec Global's CEO?

39 employees have rated Oxford Immunotec Global CEO Peter Wrighton-Smith on Glassdoor.com. Peter Wrighton-Smith has an approval rating of 75% among Oxford Immunotec Global's employees.

Who are some of Oxford Immunotec Global's key competitors?

What other stocks do shareholders of Oxford Immunotec Global own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include Dynavax Technologies (DVAX), AbbVie (ABBV), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Immunomedics (IMMU), Intel (INTC), Iovance Biotherapeutics (IOVA), Gold Resource (GORO), Inovio Pharmaceuticals (INO) and Netflix (NFLX).

What is Oxford Immunotec Global's stock symbol?

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

Who are Oxford Immunotec Global's major shareholders?

Oxford Immunotec Global's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Endurant Capital Management LP (8.63%), Alyeska Investment Group L.P. (5.17%), Alyeska Investment Group L.P. (5.17%), Renaissance Technologies LLC (1.97%), New York State Common Retirement Fund (1.34%) and Dimensional Fund Advisors LP (1.28%). Company insiders that own Oxford Immunotec Global stock include Patrick J Balthrop, Peter Wrighton-Smith and Richard A Sandberg.
View institutional ownership trends for Oxford Immunotec Global
.

Which institutional investors are selling Oxford Immunotec Global stock?

OXFD stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Alyeska Investment Group L.P., Renaissance Technologies LLC, Water Island Capital LLC, Russell Investments Group Ltd., Oppenheimer & Co. Inc., New York State Common Retirement Fund, and Essex Investment Management Co. LLC.
View insider buying and selling activity for Oxford Immunotec Global
or view top insider-selling stocks.

Which institutional investors are buying Oxford Immunotec Global stock?

OXFD stock was bought by a variety of institutional investors in the last quarter, including Endurant Capital Management LP, GSA Capital Partners LLP, Dimensional Fund Advisors LP, and Wells Fargo & Company MN. Company insiders that have bought Oxford Immunotec Global stock in the last two years include Patrick J Balthrop, and Peter Wrighton-Smith.
View insider buying and selling activity for Oxford Immunotec Global
or or view top insider-buying stocks.

How do I buy shares of Oxford Immunotec Global?

Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oxford Immunotec Global's stock price today?

One share of OXFD stock can currently be purchased for approximately $21.99.

How much money does Oxford Immunotec Global make?

Oxford Immunotec Global has a market capitalization of $570.90 million and generates $73.71 million in revenue each year. The company earns $-1,810,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.

How many employees does Oxford Immunotec Global have?

Oxford Immunotec Global employs 273 workers across the globe.

What is Oxford Immunotec Global's official website?

The official website for Oxford Immunotec Global is www.oxfordimmunotec.com.

Where are Oxford Immunotec Global's headquarters?

Oxford Immunotec Global is headquartered at 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ.

How can I contact Oxford Immunotec Global?

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.